跳至主要内容
临床试验/NCT03919721
NCT03919721Unknown不适用

Phase II Field Test of Motivity.Net - Therapy Management System for Model-Based Behavioral Interventions

Experiad LLC2 个研究点 分布在 1 个国家目标入组 12 人开始时间: 2019年11月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
发起方
Experiad LLC
入组人数
12
试验地点
2
主要终点
Impact of software on trial success rate

研究概览

简要总结

This is a study funded by a Phase II SBIR to build and test the feasibility of a new software prototype for delivering evidence-based behavioral therapy treatment for autism. The software, called Motivity.net, will be used by behavioral therapy provider groups across the country to manage the intensive data collection and analysis workflow associated with Applied Behavioral Analysis (ABA) and related therapies, which are becoming standard-of-care treatment for children with autism.

详细描述

This is a study funded by a Phase II SBIR to build and test the feasibility of a new software prototype for delivering evidence-based behavioral therapy treatment for autism. The software, called Motivity.net, will be used by behavioral therapy provider groups across the country to manage the intensive data collection and analysis workflow associated with Applied Behavioral Analysis (ABA) and related therapies, which are becoming standard-of-care treatment for children with autism. Experiad will conduct an 8-week within-subject pilot study of 6 BCBAs, 12 BTs and 12 children to answer product research questions about Motivity's ability to perform its intended functions, measuring the degree to which it allows interventionists to encode their models, achieve more efficient program management, improve communication, and increase responsiveness to a child's progress. Experiad will also use descriptive statistics to provide preliminary insight into the potential impact of the system on a child's performance in their ABA therapy.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Other
盲法
None

入排标准

年龄范围
2 Years 至 21 Years(Child, Adult)
性别
All
接受健康志愿者

入选标准

  • Child receiving applied behavior analysis at participating institution to treat autism disorder

排除标准

  • 未提供

研究组 & 干预措施

Learners receiving Applied Behavior Analysis therapy

Experimental

All children enrolled in the study will already receiving therapy. Each BT-child pair will have worked together regularly for at least 3 months prior to the study.

干预措施: Applied Behavioral Analysis (Behavioral)

结局指标

主要结局

Impact of software on trial success rate

时间窗: Data will be collected continuously from start to end of study; totals will be analyzed at the end of study (8 weeks from start date)

Comparison of overall trial success rate (percent of trails meeting success threshold) in electronic administered programs compared to paper administered programs

Impact of software on number of updates to programs made by behavior analysts (intervention agility)

时间窗: Data will be collected continuously from start to end of study; totals will be analyzed at the end of study (8 weeks from start date)

Comparing the frequency of program updates between electronic programs and paper programs

Event tracking usability assessed by user ratings

时间窗: Likert scale to be administered at the end of study (8 weeks from start date)

Number of tutors who rate it highly on likert scale

Program editing efficiency as assessed by usage analysis

时间窗: Time will be tracked continuously from start to end of study; totals will be analyzed at the end of study (8 weeks from start date)

Comparison of total time spent editing electronic programs vs paper programs.

Impact of software on trials to criterion (number of trials needed to achieve mastery)

时间窗: Data will be collected continuously from start to end of study; totals will be analyzed at the end of study (8 weeks from start date)

Comparison of trials to criterion (number of trials needed to achieve mastery) in electronic administered programs compared to paper administered programs

Impact of software on total number of targets mastered

时间窗: Data will be collected continuously from start to end of study; totals will be analyzed at the end of study (8 weeks from start date)

Comparison of total number of targets mastered in electronic administered programs compared to paper administered programs

次要结局

未报告次要终点

研究者

发起方
Experiad LLC
申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验

进行中(未招募)
1 期
A study with the aim to evaluate the antitumor activity of a new association of oral drugs, lenalidomide and clarithromycin in patients with lymphoma (MALT), when standard treatment with radiation therapy, chemotherapy and / or immunotherapy have shown a lack of efficacy.Patients with lymphoid tissue lymphoma mucosa-associated (MALT) for which the standard treatments with radiotherapy, chemotherapy and / or immunotherapy show lack of efficacy.MedDRA version: 21.0Level: PTClassification code 10015823Term: Extranodal marginal zone B-cell lymphoma (MALT type) recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: PTClassification code 10015824Term: Extranodal marginal zone B-cell lymphoma (MALT type) refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2015-003168-35-ITIELSG - INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP68
进行中(未招募)
1 期
A phase II trial clarithromycin + lenalidomide combination:for patients with relapsed/refractory extranodal marginal zone lymphomaextranodal marginal zone lymphoma (MALT)
EUCTR2015-003168-35-ATIELSG International Extranodale Lymphoma Study Group; Instituto Oncologico della Svizzera Italiana,68
已完成
不适用
Development and Pilot Testing of the Sense2Quit AppSmoking CessationHIV Infections
NCT05609032Columbia University60
招募中
2 期
A Phase II pilot study to determine protocol feasibility, and potential efficacy for disease modification of combined Doxycycline and Ambroxol in Dementia with Lewy BodiesDementia with Lewy BodiesNeurological - Dementias
ACTRN12623000004662niversity of Sydney32
进行中(未招募)
不适用
Estudio piloto de fase IIb para evaluar la actividad antivírica de una pauta que contiene GSK1349572 en sujetos adultos infectados por el VIH-1 con resistencia al raltegravir que habían recibido tratamiento previo con antirretrovirales (ART) - Vicking
EUCTR2009-010270-37-ESGlaxoSmithKline S.A.30